Tag
This study compares outcomes after allogeneic stem cell transplantation using post-transplant cyclophosphamide in AML patients achieving first remission with one versus two induction courses, revealing similar survival but higher relapse wi
The INTERACT-ION phase 2 trial reports that induction ezabenlimab with modified DCF followed by biomarker-guided, involved-node radiotherapy produced high clinical complete response rates (overall 77.8%) with a manageable safety profile in
This study reveals that total tumor volume (TTV) more accurately predicts overall survival and response to induction chemotherapy than RECIST1.1 in colorectal cancer liver metastases, offering a promising tool for personalized treatment dec
This phase 3 trial compares induction-concurrent chemotherapy with concurrent-adjuvant chemotherapy in high-risk N2 to N3 nasopharyngeal carcinoma, finding no significant difference in 3-year progression-free survival while highlighting dis
A multicenter phase 3 trial demonstrates that sequential chemoradiotherapy is noninferior to induction plus concurrent chemoradiotherapy for stage III/IVA nasopharyngeal carcinoma with fewer acute toxicities.
A phase 3 trial showed no significant difference in 3-year progression-free survival between induction-concurrent and concurrent-adjuvant chemoradiotherapy in treating high-risk N2-N3 nasopharyngeal carcinoma, with both regimens exhibiting
